Tetanus Gamma Mechanism of Action

Pharmacotherapeutic Group: Immune sera and immunoglobulins. Human tetanus immunoglobulin. ATC Code: J06BB02.
Pharmacology: Pharmacodynamics: Human tetanus immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against the toxin produced by the bacteria Clostridium tetanus.
Pharmacokinetics: Absorption: Human tetanus immunoglobulin for intramuscular administration is bioavailable in the recipient's circulation after a delay of 2-3 days.
Elimination: Human tetanus immunoglobulin has a half-life of about 3-4 weeks. This half-life may vary from patient to patient.
IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.
Toxicology: Preclinical safety data: Immunoglobulin is normal constituent of the human body.
In animals, single dose toxicity testing is of no relevance since higher doses result in overloading. Repeated dose toxicity testing and embryo-foetal toxicity studies are not practicable due to induction of, and interference with antibodies. Effects of the immunoglobulins on the immune system of the newborn have not been studied.
Since clinical experience provides no hint for tumorigenic and mutagenic effects of immunoglobulin, experimental studies, particularly in heterologous species, are not considered necessary.